The lung function score and its components as predictors of overall survival and chronic graft-vs-host disease after allogeneic stem cell transplantation

**Aim** To retrospectively assess if the modified lung function score (LFS) and/or its components, forced expiratory volume within the first second (FEV1) and diffusion capacity for carbon monoxide corrected for hemoglobin level (cDLCO), predict overall survival (OS) and chronic graft-vs-host-disease (cGvHD).

**Methods** We evaluated 241 patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the University of Regensburg Transplant Center between June 1998 and July 2005 in relation to their LFS, FEV1, and cDLCO, before and after HSCT.

**Results** Decreased OS after allo-HSCT was related to decreased pre-transplantation values of FEV1 <60% (P = 0.040), cDLCO <50% of predicted value (P = 0.025), and LFS ≥III (P = 0.037). It was also related to decreased FEV1 at 3 and 12 months after HSCT (P < 0.001 and P = 0.001, respectively) and increased LFS at 3 and 12 months after HSCT (P = 0.028 and P = 0.002, respectively), but not to changes of cDLCO. A higher incidence of cGvHD was related to decreased FEV1 at 6, 12, and 18 months (P = 0.069, P = 0.054, and P = 0.009, respectively) and increased LFS at 12 months (P = 0.002), but not to changes in cDLCO.

**Conclusions** OS was related to both LFS and FEV1, but cGvHD had a stronger relation to FEV1 than to cDLCO or LFS. FEV1 alone offered more information on the outcome after allo-HSCT than LFS or cDLCO, suggesting limited value of LFS for the patients’ assessment after allo-HSCT.
Pulmonary complications significantly contribute to late-onset morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-H SCT). Patients with pulmonary dysfunction surviving longer than 2 years had a 15.1-fold increased risk of late mortality than the general population (1). Late onset non-infectious pulmonary complications can present in different forms, such as restrictive changes on pulmonary function testing (PFT) only, late interstitial pneumonitis (IP), cryptogenic organizing pneumonia (COP), airflow obstruction detected by PFT only, or bronchiolitis obliterans (BO)/bronchiolitis obliterans syndrome (BOS). Both, restrictive or obstructive changes can occur isolated or in combination (2-5). Although the only currently accepted form of chronic graft-vs-host-disease (cGvHD) of the lung is BO/BOS, it seems that all forms can occur associated with cGvHD and, although not pathophysiologically fully understood, may reflect potential overlapping forms or different phenotypes of pulmonary cGvHD (2-11). BO/BOS is presumably the most detrimental form characterized by frequent non-responsiveness to treatment, progressive clinical course, and irreversibility, all of which contributes to its high morbidity and mortality (12,13).

cGvHD is a major complication in long-term survivors after allo-HSCT (1,14,15), with a 6-year incidence of up to 61% in patients receiving peripheral blood stem cells (PBSC) (15) and with relevant impact on the quality of life in many patients (16-18).

The lung function score (LFS) combines the forced expiratory volume in the first second (FEV1) and the diffusion capacity of the lung for carbon monoxide corrected for hemoglobin level (cDLCO) in an equally distributed manner. The LFS was first proposed by Parimon et al (19) as an approach to correlate PFT results prior to allo-HSCT with the clinical outcome. Later it was modified into more precise subcategories by the National Institute of Health (NIH) Consensus Development Project on the criteria for clinical trials in cGvHD (Table 1) and suggested as a score to quantify pulmonary cGvHD and evaluate the effect of cGvHD treatment (20). In our clinical practice, we have seen cDLCO decreasing already after induction of treatment and remaining low for several months after allo-HSCT without obvious impact on the outcome. Therefore the aim of this study was to evaluate the association of pre- and post-HSCT LFS, defined according to the NIH consensus development project definition (20), and the LFS constituting parameters cDLCO and FEV1, individually, with overall survival (OS) and development of cGvHD after allo-HSCT.

**PATIENT CHARACTERISTICS AND METHODS**

**Patient characteristics**

This retrospective single-center study included 241 out of 247 adult patients of Caucasian origin who received allo-HSCT at the University of Regensburg Medical Center, Regensburg, Germany between June 1998 and July 2005; 6 patients were excluded due to missing data on pulmonary function before allo-HSCT. The median follow-up was 711 days (range, 22-3091 days) and the last day of recording data was March 31, 2007. Mean age was 44.5 years, 39% of patients were female and 69% male, 48% had a related and 52% an unrelated donor, 46% of patients had Eastern Cooperative Oncology Group (ECOG) index 0, 46% had ECOG index 1, and only 2% had ECOG index 2.

Prior to transplant, patients gave informed consent on the use of patient- and treatment-related information for retrospective analyses and publication. Standard myeloablative conditioning regimens consisted mainly of 8-12 Gy fractionated total body irradiation followed by high dose cyclophosphamide +/− fludarabine or classic busulfan/cyclophosphamide, whereas reduced intensity conditioning (RIC) consisted mainly of the FBM (fludarabine/BCNU/melphalan) regimen (21). T-cell depletion for unrelated donor HSCT was performed by serotherapy with antithymocyte globulin (ATG) in 147 patients, with alemtuzumab in 4 patients, and with ex vivo selection of donor CD34+ cells in

**TABLE 1. Lung function score (LFS) according to Pavletic et al (20)**

| FEV1 in % of predicted | cDLCO in % of predicted | Score | Σ score (FEV1 + cDLCO) | LFS |
|------------------------|-------------------------|-------|------------------------|-----|
| >80                    | >80                     | 1     | Normal                 | 2   |
| 70-79                  | 70-79                   | 2     | Mild decrease          | 3 - 5|
| 60-69                  | 60-69                   | 3     | Moderate decrease      | 6 - 9|
| 50-59                  | 50-59                   | 4     | Severe decrease        | 10 - 12|
| 40-49                  | 40-49                   | 5     |                        | IV  |
| <40                    | <40                     | 6     |                        |     |

*FEV1 – forced expiratory volume in the first second; cDLCO – diffusion capacity of the lung for carbon monoxide corrected for hemoglobin level.*
The severity of acute GvHD was graded from 0 to 4 using the Glucksberg scale (22). cGVHD was classified into no, limited, and extensive disease according to Shulman et al (23) and grouped by the presence or absence of cGvHD (Table 2).

PFT was scheduled before allo-HSCT and 3, 6, 9, and 12 months after transplant. Thereafter, patients were supposed to return to the center at 6-month intervals for follow-up or at shorter intervals if clinical complications were present. PFT was performed in our center according to the guidelines of the European Respiratory Society using the MasterScreen Body (Viasys Health Care, Würzburg, Germany) including spirometry, body plethysmography, and diffusion capacity measurements using the single breath method. The data were digitally stored. The following variables were considered longitudinally: vital capacity (VC), total lung capacity (TLC), FEV_{1}, FEV_{1}/VC-ratio, and the diffusion capacity using the single-breath method (DLCO). This study focused only on FEV_{1} and cDLCO. Because LFS is composed of percentage of predicted values of cDLCO and FEV_{1}, we also used percentages of predicted values for better comparability. Predicted va-

### TABLE 2. Patient characteristics regarding allo-HSCT and disease. Stage of disease is defined as 1 for first complete remission of acute leukemia or non-Hodgkin lymphoma or chronic phase of chronic myeloid leukemia)*

| Characteristics | n = 241 (%) |
|-----------------|------------|
| Sex             |            |
| female          | 95 (39)    |
| male            | 146 (61)   |
| Disease         |            |
| acute leukemia, myelodysplastic syndrome | 127 (53) |
| chronic myeloid leukemia | 25 (10)  |
| Hodgkin’s disease | 6 (3)   |
| non-Hodgkin lymphoma | 45 (19)  |
| multiple myeloma | 18 (7)   |
| myeloproliferative disease | 10 (4) |
| other           | 10 (4)     |
| Stage of disease at allogeneic hematopoietic stem cell transplantation (allo-HSCT) | |
| 1               | 36 (15)    |
| >1              | 204 (85)   |
| NA              | 1 (0)      |
| Therapeutic radiation | |
| yes             | 22 (9)     |
| no              | 219 (91)   |
| Smoker          |            |
| yes             | 86 (36)    |
| no              | 135 (56)   |
| NA              | 20 (8)     |
| Pulmonary disease before allo-HSCT | |
| yes             | 57 (24)    |
| no              | 147 (61)   |
| NA              | 37 (15)    |
| Donor type      |            |
| matched related donor | 115 (48) |
| matched unrelated donor | 126 (52) |
| Treatment related mortality | |
| yes             | 66 (27)    |
| no              | 175 (73)   |
| Eastern Cooperative Oncology Group index before allo-HSCT | |
| 0               | 111 (46)   |
| 1               | 111 (46)   |
| 2               | 5 (2)      |
| Cytomegaly virus reactivation risk | |
| negative/negative | 93 (39)  |
| donor negative/recipient positive | 41 (17)  |
| donor positive/recipient negative positive/positive | 39 (16)  |
| NA              | 66 (27)    |
| Conditioning regimen | |
| reduced intensity conditioning | 126 (52) |
| myeloablative   | 115 (48)   |

24 patients. The severity of acute GvHD was graded from 0 to 4 using the Glucksberg scale (22). cGVHD was classified into no, limited, and extensive disease according to Shulman et al (23) and grouped by the presence or absence of cGvHD (Table 2).

PFT was scheduled before allo-HSCT and 3, 6, 9, and 12 months after transplant. Thereafter, patients were supposed to return to the center at 6-month intervals for follow-up or at shorter intervals if clinical complications were present. PFT was performed in our center according to the guidelines of the European Respiratory Society using the MasterScreen Body (Viasys Health Care, Würzburg, Germany) including spirometry, body plethysmography, and diffusion capacity measurements using the single breath method. The data were digitally stored. The following variables were considered longitudinally: vital capacity (VC), total lung capacity (TLC), FEV_{1}, FEV_{1}/VC-ratio, and the diffusion capacity using the single-breath method (DLCO). This study focused only on FEV_{1} and cDLCO. Because LFS is composed of percentage of predicted values of cDLCO and FEV_{1}, we also used percentages of predicted values for better comparability. Predicted va-
ues were calculated according to Cotes et al and Quanjer et al (24,25) and DLCO was adjusted to the hemoglobin level (cDLCO).

Statistical analysis

All statistical analyses were performed using SPSS, 23.0 (IBM, Corporation, Armonk, NY, USA). ¥² test was used to compare two categorical variables and analysis of variance was used to compare multiple categorical variables. Brown-Forsythe test was used if homoscedasticity was not assumed. Post-hoc analysis was done with the Scheffé procedure or, in case of unequal distribution of variances, with Dunnett-T3 test. For description of the time course of pulmonary function parameters matched-pair analysis was used. For OS, actuarial curves were obtained by the Kaplan-Meier analysis and compared using the log-rank test. To assess the relation between LFS, cDLCO, and FEV¹, and the development of cGvHD, Cox-regression analysis was used. Stem cell source, GvHD prophylaxis, acute GvHD, related or unrelated donor, female donor into male recipient, reduced intensity or myeloablative conditioning, busulfan in the conditioning regimen, ECOG before HSCT, CMV-reactivation risk, thoracic radiation, total body irradiation, history of smoking, age over 40 years, and T-cell depletion were tested in a forward and backward analysis as covariates. As acute GvHD (none or grade 1 vs grade 2-4: hazard ratio [HR] 1.855 [1.204-2.857], P = 0.005) and reduced intensity vs myeloablative conditioning (HR 1.584 [1.027-2.441], P = 0.037) had significant influence on the development of cGvHD, these covariates were included in the final analysis. In all analyses a two-sided significance level of α = 0.050 was considered significant.

RESULTS

Time course of FEV¹, cDLCO, and LFS after allo-HSCT

Changes over time of cDLCO, FEV¹, and LFS in surviving patients are demonstrated in Figure 1. Pre-allo HSCT cDLCO values significantly correlated with cDLCO up to 4 years after allo-HSCT, pre-allo HSCT FEV¹ values significantly correlated with FEV¹, up to 6 years after allo-HSCT, and pre-HSCT LFS significantly correlated with LFS values up to 4 years after allo-HSCT (data not shown).

cDLCO and FEV¹ showed a weak but significant positive correlation before allo-HSCT (r = 0.4421; Figure 2A), at 3 months (r = 0.3773; Figure 2B), at 6 months (r = 0.4016; Figure 2C) and at 12 months after allo-HSCT (r = 0.3135; Figure 2D), and changes in cDLCO more than those in FEV¹ contributed to an increase in LFS.
Influence of pre- and post-transplantation pulmonary function on overall survival

We next determined the influence of pre-transplantation PFT parameters on clinical outcome. Pre-HSCT cDLCO showed no linear relation with OS (Figure 3A). Yet, patients with cDLCO<50% of predicted value had significantly lower OS than patients with cDLCO≥50% (20.0% vs 41.1%, P = 0.025, Figure 3C). After we classified pre-HSCT FEV1 values by 10% increments, a trend but not a significant impact of decreased FEV1 on OS was observed (P = 0.052, Figure 3B). However, patients with pre-HSCT FEV1<60% of predicted value had significantly shorter OS than patients with pre-HSCT FEV1≥60% (0% vs 38.4%, P = 0.040, Figure 3D).

After allo-HSCT, no relation between OS and cDLCO was seen at 3 (P = 0.187; Figure 3E) and 12 months (P = 0.090; Figure 3G). In contrast, decreased FEV1 demonstrated a significant relation with OS at both time points (both P < 0.001, Figure 3F+H).

Although no significant relation was found between pre-HSCT LFS and OS, shorter OS was observed with an increase in LFS grade, but the trend was not significant (5-year OS LFS I: 41.2%; LFS II: 36.8%; LFS III: 26.7%, P = 0.191, Figure 4A), suggesting LFS≥III can be considered a predictive threshold of shorter survival. Patients with a pre-HSCT LFS III/IV had a shorter overall survival than patients with pre-HSCT LFS I/II (307 vs 918 days respectively, P = 0.069, Figure 4B).

OS was significantly shorter in patients with a baseline LFS III compared to patients with LFS I (median OS 307 vs 2208 days, P = 0.037, not shown).

After HSCT, increased LFS showed strong influence on OS at both 3 (P = 0.028; Figure 4C) and 12 months (P = 0.002; Figure 4E), confirming LFS III/IV as a critical threshold at either time point (3 months: P = 0.005; Figure 4D; 12 months: P = 0.001; Figure 4F).

Relationship between cGvHD and LFS

LFS has been proposed as a parameter in the assessment of chronic pulmonary GvHD (20). Therefore, we tested whether LFS values predicted the occurrence of cGvHD in our patient cohort. Of the 241 patients, 109 (45%) developed cGvHD, 14.7% until day +120, 25% until day +142, 50% until day +180, 75% until day +229, and 87% after one year (median time of onset: 180 days, range 94-1912 days). As mentioned above, acute GvHD (none or grade 1

---

**FIGURE 2.** Linear regression curves of forced expiratory volume in the first second (FEV1) and carbon monoxide corrected for hemoglobin level (cDLCO) in percentages of predicted value before allo-hematopoietic stem cell transplantation (HSCT) (A), P < 0.001), and 3 (B), P < 0.001), 6 (C), P < 0.001), and 12 months (D), P < 0.001) after it.
FIGURE 3. Overall survival in relation to diffusion capacity for carbon monoxide corrected for hemoglobin level (cDLCO) and forced expiratory volume in the first second (FEV₁) values before allogeneic hematopoietic stem cell transplantation (allo-HSCT) (A-D), and at 3 and 12 months (E-H) after allo-HSCT. Pulmonary function testing (PFT) intervals for cDLCO and FEV₁ are grouped as follows: 1: ≥80%; 2: 70%-80%; 3: 60%-70%; 4: 50%-60%; 5: <50% of predictive value in panel (A), (B), and (E-H); in panel C, cDLCO is divided in ≥50% vs <50%; and in panel (D), FEV₁ is grouped in ≥60% vs <60% of predicted value. Linear P values obtained using log rank test are: panel (A) (P = 0.351), panel (B) (P = 0.025), panel (E) (P = 0.187), panel (G) (P = 0.090), panel (C) (P = 0.052), panel (D) (P = 0.040), panel (F) (P < 0.001), and (H) (P < 0.001).
vs grade 2-4: HR 1.855 (1.204-2.857), \( P = 0.005 \) and reduced intensity vs myeloablative conditioning (HR 1.584 [1.027-2.441], \( P = 0.037 \) had significant influence on the development of cGvHD in the unadjusted model, resulting in the inclusion of these covariates in the final analysis.

Three months after HSCT, we evaluated cDLCO in 122 patients and FEV\(_\text{i} \) in 125 patients. Out of these, 69 and 72 patients, respectively, developed cGvHD. Neither in the adjusted nor in the unadjusted Cox-regression model LFS, cDLCO, and FEV\(_\text{i} \) were related to the development of cGvHD (not shown).

Six months after allo-HSCT, we evaluated cDLCO in 122 patients and FEV\(_\text{i} \) in 126 patients. Out of these, 74 and 75 patients, respectively, developed cGvHD. Unadjusted Cox-regression model showed that decreased FEV\(_\text{i} \) was significantly related to the development of cGvHD (\( P = 0.030 \), not shown), while changes in cDLCO and LFS were not. After adjustment for acute GvHD and conditioning regimen (re-

---

**FIGURE 4.** Overall survival in relation to lung function score (LFS) values before allogeneic hematopoietic stem cell transplantation (allo-HSCT) (A, B), at 3 (C, D) and at 12 months (E, F) after allo-HSCT. LFS grades I-IV as defined in Table 1 (A, C, E) and grouped into I and II vs III and IV in B, D and F. Linear \( P \) values obtained using log rank test are panel (A) (\( P = 0.191 \)), panel (B) (\( P = 0.069 \)), panel (C) (\( P = 0.028 \)), panel (E) (\( P = 0.002 \)), panel (D) (\( P = 0.005 \)), and panel (F) (\( P = 0.001 \)).
duced intensity vs myeloablative), there was still a relation between decreased FEV1 and development of cGVHD but it was not significant anymore ($P = 0.069$, Table 3), which might be due to very small number of patients with decreased FEV1.

One year after allo-HSCT, cDLCO was evaluated in 111 and FEV1 in 116 patients, out of these 71 and 72, respectively, developed cGVHD. Both adjusted and unadjusted Cox-regression model showed a significant influence of LFS on the development of cGVHD ($P = 0.002$ for both). In the unadjusted model decreased FEV1 showed a trend toward a relation with the occurrence of cGVHD ($P = 0.107$, not shown), which became almost significant in the adjusted model (Table 3; $P = 0.054$). There was no relation between cDLCO and cGVHD development.

Eighteen months after allo-HSCT, cDLCO was evaluated in 104 and FEV1 in 106 patients. Out of these, 67 patients developed cGVHD at the time of PFT or subsequently. Only FEV1 showed a significant influence on cGVHD in the un-adjusted and adjusted model (not shown, $P=0.036$ and 0.009, respectively).

**Decrease in FEV1 after day +90 and incidence of cGVHD**

We further determined the difference in FEV1 at day +180 and day +365 compared to day +90, as well as at day +180 compared to day +365, and considered a 10% decrease as relevant. A decrease of more than 10% from day +90 to day +180 was seen in 19 out of 83 patients in whom PFT was done; from day +90 to day +365 in 23 of 87 patients; and from +180 and day +365 in 16 of 89 patients.

The incidence of treatment related mortality did not significantly differ between the patients with a relevant FEV1 decline and the patients with stable or increased FEV1 between day +90 and day +180 as well as between day +90 and day +365, but it increased in patients with a FEV1 decline between day +180 to day +365 from 5.5 to 25% (Table 4). In addition, 15 patients with a decrease in FEV1 between day +180 and day +365 had a higher incidence of

| Parameter | Day +180 | Day +365 |
|-----------|----------|----------|
| LFS grade | $N$ | adjusted HR (95% CI) | $P$ | $N$ | adjusted HR (95% CI) | $P$ |
| I | 33 | referent | 28 | referent |
| II | 70 | 0.779 (0.457-1.330) | 0.360 | 69 | 0.970 (0.546-1.721) | 0.916 |
| III | 19 | 0.788 (0.370-1.677) | 0.536 | 13 | 3.313 (1.547-7.095) | 0.002 |
| IV | 0 | 1 | 3.540 (0.451-27.804) | 0.229 |
| trend | 0.640 | trend | 0.002 |
| FEV1, >80% | 103 | referent | 91 | referent |
| 70%-80% | 15 | 0.852 (0.407-1.784) | 0.671 | 15 | 1.418 (0.719-2.796) | 0.313 |
| 60%-70% | 6 | 1.419 (0.432-4.661) | 0.564 | 7 | 3.029 (1.170-7.844) | 0.022 |
| 50%-60% | 1 | 27.423 (2.783-270.184) | 0.005 | 0 | 0 |
| 40%-50% | 1 | 0 (0-8.66x10^213) | 0.970 | 3 | 2.605 (0.775-8.761) | 0.122 |
| <40% | 0 | 0 | 0 |
| trend | 0.069 | trend | 0.054 |
| cDLCO, >80% | 34 | referent | 30 | referent |
| 70%-80% | 24 | 0.701 (0.349-1.407) | 0.317 | 29 | 0.885 (0.453-1.728) | 0.720 |
| 60%-70% | 34 | 0.742 (0.406-1.356) | 0.333 | 30 | 0.963 (0.497-1.867) | 0.911 |
| 50%-60% | 20 | 0.545 (0.249-1.194) | 0.129 | 17 | 1.568 (0.723-3.403) | 0.256 |
| 40%-50% | 8 | 1.346 (0.507-3.576) | 0.551 | 4 | 2.867 (0.952-8.629) | 0.061 |
| <40% | 2 | 1.604 (0.373-6.901) | 0.525 | 1 | 3.000 (0.382-23.581) | 0.296 |
| trend | 0.439 | trend | 0.241 |

*$HR$ – hazard ratio; LFS – lung function score; FEV1 – forced expiratory volume in the first second; cDLCO – diffusion capacity of the lung for carbon monoxide corrected for hemoglobin level.
cGvHD (93.8 vs 53.4%), pulmonary GvHD (56.3 vs 11.0%), and a lower OS (56.3 vs 82.2%) than 39 patients with stable FEV₁ in this period. In contrast, OS did not differ between patients with or without FEV₁ decline between day +90 and day +180 or day +90 and day +365. The incidence of pulmonary cGvHD did not differ in patients with or without FEV₁ decline between day +90 and day +180, whereas the incidence of lung disease in patients with a decline of FEV₁>10% between day +90 and day +365 was 26.1% compared to 9.4% only in patients with stable FEV₁. The incidence of cGvHD irrespective of specific organ manifestations did not significantly differ (47.4% vs 59.5% day +90 until +180; 65.2% vs 56.3% day +90 until day +365) between patients with a FEV₁ decline and those with stable FEV₁ (Table 4).

DISCUSSION

A promising approach to improve the understanding and treatment of cGvHD was the NIH Consensus Development Project on criteria for clinical trials in cGvHD. One goal of this project was to improve the clinical assessment of pulmonary cGvHD by proposing LFS as a grading score for pulmonary cGvHD (20). In the new diagnostic and response criteria of the National Institutes of Health Consensus Development Project, the lung function score (26,27) is no longer recommended and FEV₁ as single parameter to assess GvHD of the lung is suggested (27), which confirms our finding that cDLCO has no relation to the development of cGvHD.

In our study, overall survival was related to FEV₁ and LFS. Pre-HSCT FEV₁ showed a higher influence on overall survival than LFS and cDLCO. FEV₁<60% and cDLCO<50% were associated with inferior survival, consistent with prior reports (28). Combining pre-HSCT cDLCO with FEV₁ may translate into better ability to identify groups at increased risk for treatment-related mortality, but this is not supported by our data.

Parimon et al (19) demonstrated a stronger relation between OS and a differently defined pre-HSCT LFS in a very large patient cohort. This discrepancy might be explained by the smaller number of patients in our study and differences in LFS categorization (in the study by Parimon et al FEV₁ and cDLCO where scored with 1 for >80%, 2 for 70%-80%, 3 for 60%-70%, and 4 for <60%, composed in a LFS grade of I for 1, II for 3-4, III for 5-6 and IV for 7-8 points).

After allo-HSCT, both decreased FEV₁ and increased LFS levels were associated with shorter OS, suggesting that both FEV₁ and LFS are useful parameters in assessing the impact of pulmonary function loss after allo-HSCT on clinical outcome. Again, while it seems reasonable to hypothesize that the LFS has a higher clinical value compared to the use of FEV₁ alone and this might result from combining the LFS constituting compounds FEV₁ and cDLCO, this was not shown in our study. According to the current guidelines of the ATS/ERS taskforce (29), FEV₁ can be used to measure the severity of obstructive and restrictive changes in pulmonary function, as either corresponds to a decrease in FEV₁. Pulmonary damage due to different patterns of pulmonary disease will be merged together within the LFS: Airflow obstruction is a common complication after allo-HSCT (30,31), and in some cases evolves from/to BO (32-34); restrictive changes, accompanied by a reduced FEV₁, have been frequently reported (10,31,32,35-37); and a reduced cDLCO has been observed in many patients already prior to allo-HSCT, often followed by a temporary decline and by a partial recovery after transplantation (28,35,38). In addition, decreased cDLCO is found in numerous pulmonary complications following allo-HSCT, not only including late onset non-infectious lung injury, but also early complications such as clinical or subclinical alveolitis and interstitial pneumonitis, pulmonary hemorrhage, engraftment syndrome or pulmonary vascular disease, and presents as reversible pulmonary toxicity secondary to conditioning regimens (4,7,29,36,39-41).
Consistent with the study by Walter et al (42), we found a significant association of FEV₁ with cGvHD at 6 and 18 months and a strong trend at 12 months after allo-HSCT. Furthermore, the incidence of cGvHD was associated with a decrease of more than 10% FEV₁ at day +365, especially between day +180 and day +365 and resulted in elevated treatment-related mortality and reduced survival. One year after allo-HSCT we also showed a significant relation of LFS with cGvHD. We also showed that cDLCO<50% potentially contributed to the LFS interrelation with cGvHD, but it alone was not related to cGvHD.

In contrast to our study, which showed no significant association between impaired FEV₁, cDLCO, and LFS values at day +90 and overall development of cGvHD, Walter et al (42) demonstrated a significant association of high LFS at day +80 with the development of cGvHD within one year after HSCT, attributing their observation mostly to a decrease in FEV₁, rather than cDLCO. The different results may be explained by a different composition of the patient-specific LFS values, as in our cohort only 5% of patients had a FEV₁ below 70% compared to 11% in the study by Walter et al. Also, a transitional decrease in lung function determined by PFT can occur in this time period post HSCT due to non-GvHD causes (38,39,43). The relatively early drop in pulmonary function, mainly reflected by a decrease in cDLCO, might be attributed to infectious complication or cytokine-mediated effects after allo-HSCT (4,7,44,45). Walter et al further restricted their data to patients developing cGvHD within one year after HSCT, whereas in our study no such time limit was set. Patients developing cGvHD at later time points can have normal LFS at day +90, therefore showing no relation between day +90 LFS and cGvHD, as observed in our cohort. Furthermore, our study population is smaller than the one evaluated by Walter et al (42), therefore our study is potentially underpowered to detect a (minor) predictive role of LFS at 3 months for survival and for Cox-regression models with up to 5 different categories as assumed by inconsistent hazard ratios for FEV₁ at 12 months as well as for FEV₁, cDLCO, and LFS at 3 months.

Another limitation of our study was that since only patients transplanted until 2005 were included in the analysis, severity grading of cGvHD was not performed according to the NIH consensus (27,46). Conditioning regimens as well as GvHD prophylaxis and treatment approaches may differ between centers, therefore possibly limiting the results of our study. However, up to now calcineurin inhibitor plus methotrexate have remained the gold standard and response rates for second line treatment in steroid refractory GvHD rates are similar across different approaches and no definite recommendation as to which is superior can be given.

Also, we compared the lung function with overall cGvHD rather than with lung GvHD. In our cohort of 241 patients, only 24 had symptomatic lung GvHD, therefore statistical analysis has to be interpreted with caution due to small patient number. During the follow-up, FEV₁ decreased slightly, which might be due to long-term toxicity, but also due to mild cGvHD not clinically affecting the lungs or cGvHD resulting in subtle changes within the lung.

This study showed that FEV₁, as a single parameter had a strong association with both OS and cGvHD at most time points before and after allo-HSCT. However cDLCO did not show such an association, which gives only limited support for the application of the LFS as defined by the NIH Consensus Project on cGvHD (20) with respect to its predictive value on transplantation outcome and its relation with cGvHD. Therefore, prospective trials investigating the value of LFS combining FEV₁ and cDLCO as a predictor of treatment response are needed. The presented results further allow to formulate clinically relevant implications, such as a) a regular screening of FEV₁ after allo-HSCT identifies patients with lung manifestations of cGvHD, while cDLCO appears to be only of clinical relevance if <50% of the predicted normal value, b) the assessment of FEV₁ at day +90 is recommended as baseline to assess the toxicity of the conditioning regimen, but is unlikely to detect changes already related to pulmonary cGvHD, c) the majority of patients developing pulmonary cGvHD show a decline of FEV₁ between day +180 and day +365 after allo-HSCT and d) reduction of FEV₁>10% compared to baseline is associated with increased morbidity and mortality. Additionally, novel parameters like acinar airways ventilation heterogeneity and lung clearance index (47) might evolve as markers for early diagnosis of pulmonary involvement in cGvHD, and their evaluation alone or in combination with LFS or FEV₁ is warranted.

**Declaration of authorship** DD contributed to the data evaluation, provided ideas for the study, and contributed to the analysis and writing. She assembles the data set and takes responsibility for data integrity. CS contributed to data collection, provided ideas for the study, and took part in writing. EW contributed to data collection and evaluation, provided ideas for the study, and took part in writing. BH contributed to data collection. EH contributed to data collection, provided ideas for the study, and took part in writing. DW contributed to data collection and evaluation, provided ideas for the study, and took part in writing. ER contributed to data collection, provided ideas for the study, and took part in writing. RR contributed to the data evaluation and provided ideas for the analysis. He takes responsibility for data integrity. CS contributed to data collection, provided ideas for the study, and took part in writing. DW received support from the German José Carreras Foundation. Ethical approval received from the Ethics Committee of the University of Regensburg, Germany.
for the study, and took part in the writing. GCH contributed to data evaluation, provided ideas for the study, and took part in the writing.

Competing interests All authors have completed the Unified Competing Interest form at www.cmj.hr (available on request from the corresponding author) and declare no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

1. Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;10:3784-92. Medline:17671231 doi:10.1182/blood-2007-03-082933

2. Bolanos-Meade J, Vogelsang GB. Chronic graft-versus-host disease. Curr Pharm Des. 2008;14:1974-86. Medline:18691108 doi:10.2174/138161208785061373

3. Cooke KR. Acute lung injury after allogeneic stem cell transplantation: from the clinic, to the bench and back again. Pediatr Transplant. 2005;9 Suppl 7:25-36. Medline:16305615 doi:10.1111/j.1399-3046.2005.00450.x

4. Cooke KR, Yanik G. Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease? Bone Marrow Transplant. 2004;34:753-65. Medline:15300233 doi:10.1038/sj.bmt.1704629

5. Tichelli A, Rovo A, Gratwohl A. Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices. Hematology (Am Soc Hematol Educ Program). 2008;1:125-33. Medline:19074070 doi:10.1182/asheducation-2008.1.125

6. Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans obliterans in recipients of hematopoietic stem cell transplants. Blood. 2003;102:3822-8. Medline:12869516 doi:10.1182/blood-2002-06-1813

7. Nishio N, Yagasaki H, Takahashi Y, Hama A, Muramatsu H, Tanaka M, et al. Engraftment syndrome following allogeneic hematopoietic stem cell transplantation in children. Pediatr Transplant. 2009;13:831-7. Medline:19067915 doi:10.1111/j.1399-3046.2008.01068.x

8. Patriarca F, Skert C, Sperotto A, Damiani D, Cerno m, Geromin, A, et al. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Bone Marrow Transplant. 2004;33:751-8. Medline:14755316 doi:10.1038/sj.bmt.1704426

9. Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y, et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood. 2003;102:4236-42. Medline:12907447 doi:10.1182/blood-2002-10-3289

10. Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:1261-9. Medline:17162207 doi:10.1016/j.bbmt.2006.07.016

11. Uderzo C, Pillon M, Corti F, Tridello G, Tana F, Zinti F, et al. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties. Bone Marrow Transplant. 2007;39:667-75. Medline:17401396 doi:10.1038/sj.bmt.1705652

12. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation: an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:5106-14. Medline:19896545 doi:10.1016/j.bbmt.2009.11.002

13. Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009;302:306-14. Medline:19602690 doi:10.1001/jama.2009.1018

14. Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant. 2010;45:295-302. Medline:19597425 doi:10.1038/bmt.2009.128

15. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood. 2006;108:4288-90. Medline:16946302 doi:10.1182/blood-2006-05-024042

16. Chiodi S, Spinelli S, Rava G, Petti AR, Van Lint MT, Lamparelli T, et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol. 2000;110:614-9. Medline:10997973 doi:10.1046/j.1365-2141.2000.02053.x

17. Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108:2867-73. Medline:16788100 doi:10.1182/blood-2006-02-030954

18. Kiss TL, Abodolel M, Jamal N, Minden MD, Lipton JH, Messner HA. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol.

www.cmj.hr
LFS and outcome of allogeneic HSCT

2002;20:2334-43. Medline:11981005 doi:10.1200/JCo.2002.06.077

19 Parimon T, Madtes DK, Au DH, Clark JG, Chien JW. Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. Am J Respir Crit Care Med. 2005;172:384-90. Medline:15894602 doi:10.1164/rccm.200502-212OC

20 Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12:252-66. Medline:16503494 doi:10.1016/j.bbmt.2006.01.008

21 Wasch R, Reisser S, Hahn J, Bertz H, Engelhardt M, Kunzmann R, et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant. 2000;26:243-50. Medline:10967561 doi:10.1038/sj.bmt.17023512

22 Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304. Medline:4153799 doi:10.1097/00007890-197401000-00001

23 Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-17. Medline:6996481 doi:10.1016/0002-9343(80)90380-0

24 Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:41-52. Medline:8499053 doi:10.1183/09041936.04151693

25 Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5-40. Medline:8499054 doi:10.1183/09041936.05051693

26 Lee SJ, Wolff D, Kitco C, Kooreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21:984-99. Medline:25796139 doi:10.1016/j.bbmt.2015.02.025

27 Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389-401.e1. Medline:25529383 doi:10.1016/j.bbmt.2014.12.001

28 Chien JW, Sullivan KM. Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility? Biol Blood Marrow Transplant. 2009;15:447-53. Medline:19285632 doi:10.1016/j.bbmt.2008.12.509

29 Pellegrino R, Viegli G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948-68. Medline:16264058 doi:10.1183/09031936.05.00035205

30 Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168:208-14. Medline:12649126 doi:10.1164/ rccm.200212-1468OC

31 Rabanus RH, Andreesen R, Holler E, Hildebrandt GC. Risk factor analysis for the development of restrictive and obstructive pulmonary function changes after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:6. doi:10.1016/j.bbmt.2007.12.019

32 Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28:425-34. Medline:11593314 doi:10.1038/sj.bmt.1703142

33 Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9:657-66. Medline:14569562 doi:10.1016/S1083-8791(03)00242-8

34 Santo Tomas LH, Loberiza FR Jr, Klein JP, Layde PM, Lipchik RJ, Rizzo JD, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest. 2005;128:153-61. Medline:16002929 doi:10.1378/chest.128.1.153

35 Marras TK, Chan CK, Lipton JH, Messner HA, Szalai JP, Laupacis A. Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation. Bone Marrow Transplant. 2004;33:509-17. Medline:14716347 doi:10.1038/sj.bmt.1704377

36 Marras TK, Szalai JP, Chan CK, Lipton JH, Messner HA, Laupacis A. Pulmonary function abnormalities after allogeneic marrow transplantation: a systematic review and assessment of an existing predictive instrument. Bone Marrow Transplant. 2002;30:599-607. Medline:12407435 doi:10.1038/sj.bmt.1703700

37 Schwerar AP, Hughes JM, Trotman-Dickenson B, Krausz T, Goldman JM. A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation. Transplantation. 1992;54:1002-8. Medline:1465767 doi:10.1097/00007890-199210000-00012

38 Gore EM, Lawton CA, Ash RC, Lipchik RJ. Pulmonary function changes in long-term survivors of bone marrow transplantation.
Kaya Z, Weiner DJ, Yilmaz D, Rowan J, Goyal RK. Lung function, pulmonary complications, and mortality after allogeneic blood and marrow transplantation in children. Biol Blood Marrow Transplant. 2009;15:817-26. Medline:19539213 doi:10.1016/j.bbmt.2009.03.019

Matute-Bello G, McDonald GD, Hinds MS, Schoch HG, Crawford SW. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant. 1998;21:1125-30. Medline:9645575 doi:10.1038/sj.bmt.1701225

Paz HL, Crilley P, Topolsky DL, Coll WX, Patchefsky A, Brodsky I. Bronchiolitis obliterans after bone marrow transplantation: the effect of preconditioning. Respiration. 1993;60:109-14. Medline:8341852 doi:10.1159/000196183

Walter EC, Orozco-Levi M, Ramirez-Sarmiento A, Vigorito A, Campregher PV, Martin PJ, et al. Lung function and long-term complications after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant. 2010;16:53-61. Medline:20053332 doi:10.1016/j.bbmt.2009.08.016

Chien JW, Martin PJ, Flowers ME, Nichols WG, Clark JG. Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;33:759-64. Medline:14968136 doi:10.1038/sj.bmt.1704422

Ferrara JL, Cooke KR, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host-disease. Stem Cells. 1996;14:473-89. Medline:8888489 doi:10.1002/stem.140473

Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893-8. Medline:11436099 doi:10.1038/sj.bmt.1703015

Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-56. Medline:16338616 doi:10.1016/j.bbmt.2005.09.004

Lahzami S, Schoeffel RE, Pechez V, Reid C, Greenwood M, Salome CM, et al. Small airways function declines after allogeneic haematopoietic stem cell transplantation. Eur Respir J. 2011;38:1180-8. Medline:21565912 doi:10.1183/09031936.00018311